Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC329358 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 231 |
0.1-0.2 | 6387 |
0.2-0.3 | 7277 |
0.3-0.4 | 11338 |
0.4-0.5 | 5205 |
0.5-0.6 | 422 |
0.6-0.7 | 16 |
0.7-0.8 | 9 |
0.8-0.85 | 1 |
0.85-0.9 | 1 |
0.9-0.95 | 2 |
0.95-1 | 0 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC329358 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 157 |
0.1-0.2 | 1402 |
0.2-0.3 | 901 |
0.3-0.4 | 3747 |
0.4-0.5 | 2596 |
0.5-0.6 | 323 |
0.6-0.7 | 30 |
0.7-0.8 | 4 |
0.8-0.85 | 0 |
0.85-0.9 | 0 |
0.9-0.95 | 1 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9439 |
High Similarity |
NPD286 |
Approved |
0.7632 |
Intermediate Similarity |
NPD9507 |
Approved |
0.7288 |
Intermediate Similarity |
NPD9376 |
Approved |
0.7016 |
Intermediate Similarity |
NPD254 |
Approved |
0.7007 |
Intermediate Similarity |
NPD521 |
Clinical (unspecified phase) |
0.6855 |
Remote Similarity |
NPD9342 |
Approved |
0.6815 |
Remote Similarity |
NPD756 |
Suspended |
0.6746 |
Remote Similarity |
NPD9247 |
Phase 3 |
0.6739 |
Remote Similarity |
NPD204 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD308 |
Approved |
0.6515 |
Remote Similarity |
NPD1158 |
Phase 2 |
0.6493 |
Remote Similarity |
NPD9723 |
Approved |
0.6484 |
Remote Similarity |
NPD313 |
Approved |
0.6434 |
Remote Similarity |
NPD965 |
Approved |
0.637 |
Remote Similarity |
NPD1160 |
Phase 2 |
0.6316 |
Remote Similarity |
NPD522 |
Approved |
0.6301 |
Remote Similarity |
NPD1084 |
Clinical (unspecified phase) |
0.6225 |
Remote Similarity |
NPD1557 |
Discontinued |
0.6214 |
Remote Similarity |
NPD1393 |
Approved |
0.6159 |
Remote Similarity |
NPD1162 |
Approved |
0.6154 |
Remote Similarity |
NPD1394 |
Approved |
0.6133 |
Remote Similarity |
NPD711 |
Discontinued |
0.6115 |
Remote Similarity |
NPD1314 |
Clinical (unspecified phase) |
0.6084 |
Remote Similarity |
NPD9279 |
Approved |
0.6084 |
Remote Similarity |
NPD6636 |
Phase 3 |
0.6042 |
Remote Similarity |
NPD822 |
Approved |
0.6038 |
Remote Similarity |
NPD9087 |
Approved |
0.6014 |
Remote Similarity |
NPD471 |
Approved |
0.6014 |
Remote Similarity |
NPD849 |
Approved |
0.6014 |
Remote Similarity |
NPD848 |
Approved |
0.6014 |
Remote Similarity |
NPD850 |
Approved |
0.6 |
Remote Similarity |
NPD9070 |
Clinical (unspecified phase) |
0.6 |
Remote Similarity |
NPD1422 |
Approved |
0.6 |
Remote Similarity |
NPD3391 |
Approved |
0.6 |
Remote Similarity |
NPD935 |
Clinical (unspecified phase) |
0.5986 |
Remote Similarity |
NPD1195 |
Approved |
0.5975 |
Remote Similarity |
NPD3511 |
Discontinued |
0.5963 |
Remote Similarity |
NPD9088 |
Approved |
0.5962 |
Remote Similarity |
NPD3241 |
Phase 2 |
0.5959 |
Remote Similarity |
NPD7083 |
Clinical (unspecified phase) |
0.5957 |
Remote Similarity |
NPD9471 |
Clinical (unspecified phase) |
0.5946 |
Remote Similarity |
NPD1196 |
Approved |
0.5946 |
Remote Similarity |
NPD2241 |
Approved |
0.5944 |
Remote Similarity |
NPD9694 |
Discovery |
0.5912 |
Remote Similarity |
NPD2341 |
Discontinued |
0.5854 |
Remote Similarity |
NPD3028 |
Approved |
0.5849 |
Remote Similarity |
NPD3252 |
Approved |
0.5828 |
Remote Similarity |
NPD2114 |
Discontinued |
0.5828 |
Remote Similarity |
NPD1543 |
Discontinued |
0.5822 |
Remote Similarity |
NPD5788 |
Clinical (unspecified phase) |
0.5813 |
Remote Similarity |
NPD3251 |
Approved |
0.5811 |
Remote Similarity |
NPD5719 |
Approved |
0.5752 |
Remote Similarity |
NPD9089 |
Approved |
0.5746 |
Remote Similarity |
NPD457 |
Approved |
0.5682 |
Remote Similarity |
NPD456 |
Approved |
0.5677 |
Remote Similarity |
NPD1678 |
Clinical (unspecified phase) |
0.5671 |
Remote Similarity |
NPD1220 |
Phase 1 |
0.5664 |
Remote Similarity |
NPD9093 |
Approved |
0.5647 |
Remote Similarity |
NPD6045 |
Phase 3 |
0.5644 |
Remote Similarity |
NPD1293 |
Approved |
0.5638 |
Remote Similarity |
NPD9274 |
Approved |
0.5638 |
Remote Similarity |
NPD9275 |
Approved |
0.5638 |
Remote Similarity |
NPD7753 |
Approved |
0.5638 |
Remote Similarity |
NPD9276 |
Approved |
0.5638 |
Remote Similarity |
NPD9278 |
Suspended |
0.5638 |
Remote Similarity |
NPD7752 |
Approved |
0.5613 |
Remote Similarity |
NPD3627 |
Approved |
0.5608 |
Remote Similarity |
NPD1169 |
Approved |
0.5605 |
Remote Similarity |
NPD3296 |
Phase 1 |
0.56 |
Remote Similarity |
NPD9277 |
Approved |
0.56
|
Remote Similarity |
NPD75 |
Approved |